Response to Drs Von Hoff and Renschler.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 6, p. 445, doi. 10.1177/1758834017709238
- By:
- Publication type:
- Article
Works matching IS 17588340 AND DT 2017 AND VI 9 AND IP 6
Results: 6
1
2
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 6, p. 431, doi. 10.1177/1758834017708742
- By:
- Publication type:
- Article
3
Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 6, p. 415, doi. 10.1177/1758834017705588
- By:
- Publication type:
- Article
4
Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 6, p. 405, doi. 10.1177/1758834017704329
- By:
- Publication type:
- Article
5
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 6, p. 387, doi. 10.1177/1758834017702820
- By:
- Publication type:
- Article
6
Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 6, p. 441, doi. 10.1177/1758834017699772
- By:
- Publication type:
- Article